1. Home
  2. CCCC vs ORGN Comparison

CCCC vs ORGN Comparison

Compare CCCC & ORGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • ORGN
  • Stock Information
  • Founded
  • CCCC 2015
  • ORGN 2008
  • Country
  • CCCC United States
  • ORGN United States
  • Employees
  • CCCC N/A
  • ORGN N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • ORGN Major Chemicals
  • Sector
  • CCCC Health Care
  • ORGN Industrials
  • Exchange
  • CCCC Nasdaq
  • ORGN Nasdaq
  • Market Cap
  • CCCC 115.0M
  • ORGN 96.4M
  • IPO Year
  • CCCC 2020
  • ORGN N/A
  • Fundamental
  • Price
  • CCCC $1.50
  • ORGN $0.70
  • Analyst Decision
  • CCCC Buy
  • ORGN Strong Buy
  • Analyst Count
  • CCCC 4
  • ORGN 1
  • Target Price
  • CCCC $12.50
  • ORGN $3.00
  • AVG Volume (30 Days)
  • CCCC 1.3M
  • ORGN 730.4K
  • Earning Date
  • CCCC 05-07-2025
  • ORGN 05-15-2025
  • Dividend Yield
  • CCCC N/A
  • ORGN N/A
  • EPS Growth
  • CCCC N/A
  • ORGN N/A
  • EPS
  • CCCC N/A
  • ORGN N/A
  • Revenue
  • CCCC $39,783,000.00
  • ORGN $31,282,000.00
  • Revenue This Year
  • CCCC N/A
  • ORGN $49.18
  • Revenue Next Year
  • CCCC $36.31
  • ORGN $144.81
  • P/E Ratio
  • CCCC N/A
  • ORGN N/A
  • Revenue Growth
  • CCCC 98.56
  • ORGN 8.60
  • 52 Week Low
  • CCCC $1.09
  • ORGN $0.42
  • 52 Week High
  • CCCC $7.66
  • ORGN $1.90
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 46.32
  • ORGN 51.08
  • Support Level
  • CCCC $1.42
  • ORGN $0.64
  • Resistance Level
  • CCCC $1.64
  • ORGN $0.75
  • Average True Range (ATR)
  • CCCC 0.15
  • ORGN 0.06
  • MACD
  • CCCC 0.02
  • ORGN 0.00
  • Stochastic Oscillator
  • CCCC 25.64
  • ORGN 26.67

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About ORGN Origin Materials Inc.

Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

Share on Social Networks: